|
US5007790A
(en)
|
1989-04-11 |
1991-04-16 |
Depomed Systems, Inc. |
Sustained-release oral drug dosage form
|
|
ATE173159T1
(de)
|
1992-03-25 |
1998-11-15 |
Depomed Systems Inc |
Auf hydroxyethylzellulose basierende oralen arzneidosisformen mit verzoegerter wirkstoffabgabe
|
|
US5582837A
(en)
|
1992-03-25 |
1996-12-10 |
Depomed, Inc. |
Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
|
|
WO1997047285A1
(en)
|
1996-06-10 |
1997-12-18 |
Depomed, Inc. |
Gastric-retentive oral controlled drug delivery system with enhanced retention properties
|
|
US5972389A
(en)
|
1996-09-19 |
1999-10-26 |
Depomed, Inc. |
Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
|
|
US6635280B2
(en)
|
1997-06-06 |
2003-10-21 |
Depomed, Inc. |
Extending the duration of drug release within the stomach during the fed mode
|
|
ES2248908T7
(es)
|
1997-06-06 |
2014-11-24 |
Depomed, Inc. |
Formas de dosificación de fármacos por vía oral y retención gástrica para liberación continuada de fármacos altamente solubles
|
|
CA2389236A1
(en)
|
1999-11-02 |
2001-05-10 |
Depomed, Inc. |
Pharmacological inducement of the fed mode for enhanced drug administration to the stomach
|
|
ES2270982T3
(es)
|
2000-02-04 |
2007-04-16 |
Depomed, Inc. |
Forma de dosificacion de nucleo y carcasa que se aproxima a una liberacion del farmaco de orden cero.
|
|
US6488962B1
(en)
|
2000-06-20 |
2002-12-03 |
Depomed, Inc. |
Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
|
|
US6451808B1
(en)
|
2000-10-17 |
2002-09-17 |
Depomed, Inc. |
Inhibition of emetic effect of metformin with 5-HT3 receptor antagonists
|
|
ATE430742T1
(de)
|
2000-12-21 |
2009-05-15 |
Smithkline Beecham Corp |
Pyrimidinamine als angiogenesemodulatoren
|
|
MXPA03011096A
(es)
|
2001-05-29 |
2004-12-06 |
Depomed Dev Ltd |
Metodo para el tratamiento de la enfermedad de reflujo gastroesofagico y la saturacion acida nocturna.
|
|
CA2409552A1
(en)
|
2001-10-25 |
2003-04-25 |
Depomed, Inc. |
Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
|
|
TWI312285B
(en)
|
2001-10-25 |
2009-07-21 |
Depomed Inc |
Methods of treatment using a gastric retained gabapentin dosage
|
|
US20030091630A1
(en)
|
2001-10-25 |
2003-05-15 |
Jenny Louie-Helm |
Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
|
|
US6723340B2
(en)
|
2001-10-25 |
2004-04-20 |
Depomed, Inc. |
Optimal polymer mixtures for gastric retentive tablets
|
|
EP1438027A1
(en)
|
2001-10-25 |
2004-07-21 |
DepoMed, Inc. |
Methods of treatment using a gastric retained losartan dosage
|
|
US6682759B2
(en)
|
2002-02-01 |
2004-01-27 |
Depomed, Inc. |
Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
|
|
WO2008080153A2
(en)
|
2006-12-22 |
2008-07-03 |
The Children's Hospital Of Philadelphia |
A novel protein kinase c therapy for the treatment of acute lung injury
|
|
US20110142837A1
(en)
*
|
2007-07-20 |
2011-06-16 |
Trustees Of The University Of Pennsylvania |
Method Of Treating Acute Respiratory Distress Syndrome
|
|
EP3067054B1
(en)
|
2007-09-10 |
2020-12-30 |
Boston Biomedical, Inc. |
Novel compositions and methods for cancer treatment
|
|
EP2259844A4
(en)
|
2008-03-05 |
2012-02-01 |
Vicus Therapeutics Llc |
COMPOSITIONS AND METHODS FOR MUCOSITIS AND ONCOLOGICAL THERAPIES
|
|
US8652476B2
(en)
|
2009-07-27 |
2014-02-18 |
Niigata University |
Pharmaceutical composition for treating ischemic events
|
|
JP5823672B2
(ja)
|
2009-07-27 |
2015-11-25 |
国立大学法人 新潟大学 |
受容体シグナル伝達阻害剤を含む脳梗塞治療用医薬品組成物
|
|
US20120107304A1
(en)
*
|
2010-04-27 |
2012-05-03 |
Boehringer Ingelheim International Gmbh |
Combination therapy in treatment of oncological and fibrotic diseases
|
|
JP2014503500A
(ja)
|
2010-11-18 |
2014-02-13 |
シンタ ファーマスーティカルズ コーポレーション |
低酸素状態に基づく酸素感受性薬剤による治療に適した被験体の事前選択
|
|
MY181439A
(en)
|
2011-02-28 |
2020-12-22 |
Sunshine Lake Pharma Co Ltd |
Substituted quinoline compounds and methods of use
|
|
KR101649610B1
(ko)
|
2011-04-21 |
2016-08-19 |
오리제니스 게엠베하 |
키나아제 억제제로서의 헤테로사이클릭 화합물
|
|
IN2014CN02850A
(enExample)
|
2011-10-31 |
2015-07-03 |
Glaxosmithkline Intellectual Property Ltd |
|
|
AU2012362370A1
(en)
|
2011-12-30 |
2014-07-24 |
Abbvie Inc. |
Dual variable domain immunoglobulins against receptors
|
|
WO2013148537A1
(en)
*
|
2012-03-29 |
2013-10-03 |
Ning Xi |
Substituted spirobicyclic compounds and methods of use
|
|
CA2919498C
(en)
|
2013-07-31 |
2023-07-25 |
Windward Pharma, Inc. |
Aerosol nintedanib compounds and uses thereof
|
|
US9951026B2
(en)
|
2013-09-17 |
2018-04-24 |
Pharmakea, Inc. |
Heterocyclic vinyl autotaxin inhibitor compounds
|
|
AU2014324566B2
(en)
*
|
2013-09-30 |
2019-01-24 |
The Texas A&M University System |
Compositions associated with and methods of managing neutrophil movement
|
|
KR101636563B1
(ko)
|
2014-01-24 |
2016-07-06 |
주식회사 엘지생명과학 |
급성 폐 손상 및 급성 호흡곤란 증후군의 예방 또는 치료용 조성물
|
|
JP6500037B2
(ja)
*
|
2014-04-22 |
2019-04-10 |
キャリター・サイエンシーズ・リミテッド・ライアビリティ・カンパニーＣａｌｉｔｏｒ Ｓｃｉｅｎｃｅｓ， Ｌｌｃ |
二環式ピラゾロン化合物および使用方法
|
|
MX2017001818A
(es)
|
2014-08-08 |
2017-05-30 |
Forsight Vision4 Inc |
Formulaciones estables y solubles de inhibidores de receptor de quinasa tirosina y metodos de preparacion de los mismos.
|
|
US11166953B2
(en)
|
2017-04-17 |
2021-11-09 |
Yale University |
Compounds, compositions and methods of treating or preventing acute lung injury
|